At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating Placebo and PF-04856883 for Diabetes Mellitus and 4 related conditions. Completed, enrolled 84 participants across 7 sites.
Detailed Summary
The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
Study Details
Timeline
Interventions
Single subcutaneous injection of placebo
Single subcutaneous injection of PF-04856883
Single subcutaneous injection of PF-04856883
Single subcutaneous injection of PF-04856883
Single subcutaneous injection of placebo
Single subcutaneous injection of PF-04856883
Single subcutaneous injection of PF-04856883
Single subcutaneous injection of PF-04856883
Multiple weekly subcutaneous injections of placebo for 3 weeks
Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks